Document is current
Any future updates will be listed below
-
Authors
Steenbruggen, Tessa G.
Wolf, Denise M.
Campbell, Michael J.
Sanders, Joyce
Cornelissen, Sten
Thijssen, Bram
Salgado, Roberto A.
Yau, Christina
O-Grady, Nick
Basu, Amrita
Bhaskaran, Rajith
Mittempergher, Lorenza
Hirst, Gillian L.
Coppe, Jean-Philippe
Kok, Marleen
Sonke, Gabe S.
van ‘t Veer, Laura J.
Horlings, Hugo M.
-
Funding
Funding for this research was provided by:
A Sister’s Hope
[Z]aan de Wandel
Nijbakker-Morra
Jo Kolk
Breast Cancer Research Foundation (17-194)
Atwater Foundation
- License Information
-
More Information
Article History
Received: 7 April 2022
Accepted: 21 September 2023
First Online: 4 October 2023
Declarations
:
: This study was approved by the Review Board of the Netherlands Cancer Institute and conducted in accordance with the Declaration of Helsinki. No informed consent was required.
: Not applicable.
: GS reports institutional research support from AstraZeneca, Merck, Novartis, and Roche outside the scope of this manuscript. HMH reports institutional research support from Roche outside the scope of this manuscript. RS reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche for an advisory board related to a trial-research project. MK reports institutional research support from AstraZeneca, BMS, Roche outside the scope of this manuscript. MK is advisory board member for BMS, Daiichi, MSD and Roche (compensated to the institute). LM and RB are employed by Agendia the commercial entity that markets the 70-gene signature as MammaPrint. LV is co-founder, stockholder and part-time employed by Agendia the commercial entity that markets the 70-gene signature as MammaPrint. TS, DW, MC, JS, SC, BT, CY, NO, AB, GH, JPC, and HH report no conflict of interest.
